Our Health Library information does not replace the advice of a doctor. Please be advised that this information is made available to assist our patients to learn more about their health. Our providers may not see and/or treat all topics found herein.

Abacavir, Dolutegravir, and Lamivudine

(a bak' a vir) (doe" loo teg' ra vir) (la miv' ue deen)

Brand Name(s): Triumeq®, Triumeq PD®

IMPORTANT WARNING:

Abacavir, dolutegravir, and lamivudine may cause a serious or life-threatening allergic reaction. Call your doctor immediately if you develop one symptom from two or more of the following groups to see if you should stop taking abacavir, dolutegravir, and lamivudine:

  • Group 1: fever
  • Group 2: rash
  • Group 3: nausea, vomiting, diarrhea, or stomach area pain
  • Group 4: generally ill feeling, extreme tiredness, or achiness
  • Group 5: shortness of breath, cough, or sore throat

Also, call your doctor immediately if you experience any of the following symptoms: headache; muscle or joint pain; swelling of the face, hands, feet, ankles, or lower legs; pain, burning, or tingling in the hands or feet; itching; blistering or peeling of the skin; difficulty swallowing or breathing; red, swollen, itchy, or teary eyes; or sores in the mouth.

Your pharmacist will give you a Warning Card when you receive your medication to carry with you. The Warning Card contains the groups of symptoms listed above to make it easy for you and the people around you to recognize if you are having an allergic reaction. Be sure to carry this Warning Card with you at all times.

Some people may be more likely to have an allergic reaction to abacavir, dolutegravir, and lamivudine based on their heredity or genetic make-up. Your doctor may order a genetic lab test prior to starting abacavir, dolutegravir, and lamivudine or if you have not been previously tested to determine if you are more likely to have an allergic reaction to this medication. Tell your doctor and pharmacist if you are allergic to abacavir, dolutegravir, and lamivudine or any other medications that contain abacavir or dolutegravir or if you know that you have that particular genetic makeup. If you have ever had a previous allergic reaction to abacavir (in Epzicom, in Trizivir, Ziagen) or dolutegravir (Tivicay) or any other medication containing abacavir or dolutegravir, your doctor will probably tell you not to take abacavir, dolutegravir, and lamivudine. If your doctor tells you to stop taking abacavir, dolutegravir, and lamivudine because you had an allergic reaction, never take abacavir, dolutegravir, and lamivudine or a medication containing abacavir or dolutegravir again. If you stop taking abacavir, dolutegravir, and lamivudine for any other reason, including missing several doses in a row or running out of medication, do not start taking it again without first talking to your doctor. You will need to be around people who can provide or call for emergency medical care, if needed, when you restart this medication.

Tell your doctor if you have or think you may have hepatitis B virus infection (HBV; an ongoing liver infection) or hepatitis C virus infection (HCV; an ongoing liver infection). If you have HBV and you take abacavir, dolutegravir, and lamivudine, your condition may suddenly worsen when you stop taking abacavir, dolutegravir, and lamivudine. Your doctor will examine you and order lab tests regularly for several months after you stop taking abacavir, dolutegravir, and lamivudine to see if your HBV has worsened.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to abacavir, dolutegravir, and lamivudine.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with abacavir, dolutegravir, and lamivudine and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Talk to your doctor about the risks of taking abacavir, dolutegravir, and lamivudine.

WHY is this medicine prescribed?

The combination of abacavir, dolutegravir, and lamivudine is used alone or along with other medications to treat HIV infection in certain adults and children 3 months or older who weigh at least 13 lb (6 kg). Abacavir and lamivudine are in a class of medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs) and dolutegravir is in a class of medications called integrase strand transfer inhibitors (INSTIs). They work by decreasing the amount of HIV in your blood and increasing the number of immune cells that help fight infections in your body. Although abacavir, dolutegravir, and lamivudine will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of getting or transmitting the HIV virus to other people.

Are there OTHER USES for this medicine?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

HOW should this medicine be used?

The combination of abacavir, dolutegravir, and lamivudine comes as a tablet to take by mouth or tablets to be dissolved into a suspension (liquid) to be taken by mouth. The tablet is usually prescribed for adults and children weighing more than 55 lb (25 kg) and taken once daily with or without food. The tablets for suspension are prescribed for children weighing less than 55 lb (25 kg) and are taken once daily with or without food. Take abacavir, dolutegravir, and lamivudine at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take abacavir, dolutegravir, and lamivudine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

If giving the tablets for suspension to a child, the tablets should be placed in the provided cup with 15-20 mL of drinking water (3 tablets can be placed in 15 mL but more than 3 tablets should be placed in 20 mL) and then swirl contents until tablets are completely dissolved and no lumps remain. After tablets are completely dissolved, the contents of the cup should be completely swallowed within 30 minutes. For children too young to drink from a cup, the contents of the cup may be drawn into a syringe and the medication given this way.

Abacavir, dolutegravir, and lamivudine help to control HIV infection but do not cure it. Continue to take abacavir, dolutegravir, and lamivudine even if you feel well. Do not stop taking abacavir, dolutegravir, and lamivudine without talking to your doctor.

What SPECIAL PRECAUTIONS should I follow?

Before taking abacavir, dolutegravir, and lamivudine,

  • tell your doctor and pharmacist if you are allergic to abacavir, dolutegravir, and lamivudine, any other medications, or any of the ingredients in abacavir, dolutegravir, and lamivudine tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.

  • tell your doctor if you are taking dofetilide (Tikosyn). Your doctor will probably tell you not to take abacavir, dolutegravir, and lamivudine if you are taking this medication.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, you are taking or plan to take. Be sure to mention any of the following: carbamazepine (Carbatrol, Equetro, Tegretol, others); dalfampridine (Ampyra); other medications for HIV including abacavir (in Epzicom, in Trizivir, Ziagen), dolutegravir (Tivicay), efavirenz (Sustiva, in Atripla), emtricitabine (Emtriva, in Atripla, in Complera, in Truvada, others), etravirine (Intelence), fosamprenavir (Lexiva) taken with ritonavir (Norvir), lamivudine (Epivir, in Combivir, in Epzicom, in Trizivir, others), nevirapine (Viramune), and tipranavir (Aptivus) taken with ritonavir (Norvir); metformin (Glumetza, Glucophage, Riomet); methadone (Dolophine, Methadose); oxcarbazepine (Oxtellar XR, Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); and sorbitol or medications that contain sorbitol. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • if you are taking antacids, laxatives, or multivitamins that contain aluminum, magnesium, or calcium; calcium supplements; iron supplements; sucralfate (Carafate); or buffered medications such as buffered aspirin, take abacavir, dolutegravir, and lamivudine at least 2 hours before or 6 hours after you take these medications.

  • tell your doctor what herbal products you are taking, especially St. John's wort. You should not take St. John's wort while you are taking abacavir, dolutegravir, and lamivudine.

  • tell your doctor if you have or have ever had liver disease. Your doctor will probably tell you not to take abacavir, dolutegravir, and lamivudine.

  • tell your doctor if you smoke or drink alcohol, or if you have or have ever had high blood pressure, high cholesterol, diabetes, or heart or kidney disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You will need to take a pregnancy test before you start treatment. You should not become pregnant while you are taking abacavir, dolutegravir, and lamivudine. Talk to your doctor about effective birth control methods that you can use during your treatment. If you become pregnant while taking abacavir, dolutegravir, and lamivudine, call your doctor immediately. Dolutegravir may harm the fetus.

  • tell your doctor if you are breastfeeding. You should not breastfeed if you are infected with HIV or if you are taking abacavir, dolutegravir, and lamivudine.

  • ask your doctor about the safe use of alcoholic beverages and medications that contain alcohol while you are taking abacavir, dolutegravir, and lamivudine.

  • you should know that while you are taking medications to treat HIV infection, your immune system may get stronger and begin to fight other infections that were already in your body. This may cause you to develop symptoms of those infections. If you have new or worsening symptoms at any time during your treatment with abacavir, dolutegravir, and lamivudine, be sure to tell your doctor.

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What should I do IF I FORGET to take a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What SIDE EFFECTS can this medicine cause?

Some side effects can be serious. If you experience any of the following symptoms, or those mentioned in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

  • excessive tiredness; weakness, dizziness, or lightheadedness; fast or irregular heartbeat; muscle pain; stomach pain with nausea and vomiting; shortness of breath or difficulty breathing; flu-like symptoms such as fever, chills, or cough; or feeling cold, especially in the arms or legs
  • light-colored bowel movements; yellowing of the skin or eyes; loss of appetite; unusual bleeding or bruising; dark yellow or brown urine; or pain in the upper right part of stomach

Abacavir, dolutegravir, and lamivudine may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What should I know about STORAGE and DISPOSAL of this medication?

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). Do not remove the desiccant (small packet included with medication to absorb moisture) from your bottle.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

What OTHER INFORMATION should I know?

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

Keep a supply of abacavir, dolutegravir, and lamivudine on hand. Do not wait until you run out of medication to refill your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Dear patient

I am excited to announce that I will be relocating my practice to Houston Methodist DeBakey Cardiology Associates. Starting November 4, 2024, my new address will be:

Houston Methodist DeBakey Cardiology Associates
6550 Fannin St.
Smith Tower, Suite 1901
Houston, TX 77030

Please note that my phone number and fax number will also change to the following:
24-Hour Telephone: 713-441-1100
Fax: 713-790-2643
Clinical Support Telephone (M-F, 8-5): 713-441-3515

I am excited about caring for you in my new office and hope you will make the transition with me. I will also continue to refill your medications as I have in the past. To assist, please provide your pharmacy with my new contact information.

Please consider checking your prescription refills to verify that you have enough medication on hand to last you until your next visit. Please note that your medical records will remain at my former office until you authorize their transfer. If you choose for me to continue providing your medical care, please complete and sign the enclosed “Authorization for Release of Medical Records” form and fax it to 713-790-2643. Once we receive your authorization, we will be happy to process the request for you.

Thank you for entrusting me with your medical care. My new team and I are dedicated to making this transition as seamless as possible. For help scheduling an appointment and transitioning your care, please call my new office number above.

I look forward to continuing your care at my new location.

Sincerely,
Gopi A. Shah, MD

Dear patient

Dr. Albert Raizner, Dr. Michael Raizner, and Dr. Mohamed El-Beheary are excited to announce that our practice, Interventional Cardiology Associates, will merge with Houston Cardiovascular Associates on November 1, 2024.

Our new offices are similarly located in Houston, near the Texas Medical Center and in Sugar Land. Our in-hospital care will continue at Houston Methodist Hospital in the Texas Medical Center and Houston Methodist Sugar Land Hospital. Importantly, our new offices expand our services with state-of-the-art equipment and amenities. Our core values will always be, as they began over 40 years ago when Dr. Albert Raizner founded ICA:

Integrity – Compassion – Accountability

Our new address and contact information are:

Your medical records are confidential and remain available at our new locations. We consider it a privilege to serve as your cardiologists and look forward to your continuing with us. However, should you desire to transfer to another physician, you may request a copy of your records by contacting us at our new addresses and phone numbers listed above.

We thank you for your trust and loyalty. As always, we will continue to be here to take care of you. Please do not hesitate to contact us if you have any questions or concerns.

Sincerely,

Dr. Albert Raizner,
Dr. Michael Raizner,
Dr. Mohamed El-Beheary